Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 3, pp 891–898 | Cite as

Prognostic Significance of Complications after Curative Surgery for Gastric Cancer

  • Takeshi Kubota
  • Naoki Hiki
  • Takeshi Sano
  • Shogo Nomura
  • Souya Nunobe
  • Koshi Kumagai
  • Susumu Aikou
  • Ryohei Watanabe
  • Toshiyuki Kosuga
  • Toshiharu Yamaguchi
Gastrointestinal Oncology

Abstract

Background

Postoperative complications such as anastomotic leakage were reported to be a major independent prognostic factor for long-term survival in gastrointestinal malignancies. This study sought to clarify the prognostic significance of postoperative inflammatory complications specifically for patients with gastric cancer.

Methods

This study included 1,395 patients who underwent curative resection for gastric cancer from 2005 to 2008. Complications were evaluated according to the Clavien-Dindo classification. Overall survival (OS) and disease-specific mortality (DSM) were compared between complication and no-complication groups. Presence of complications was modeled by the Cox proportional hazard model for OS and the Fine and Gray competing risk regression model for DSM to assess the correlation between complication and prognosis.

Results

The median follow-up time was 3.1 years. Two hundred seven patients (14.8 %) had complications of grade 2 or higher. Of 131 patients who died within this period, 87 died of gastric cancer. The 3-year OS in the complication group was 84.1 % compared to 93.1 % in the no-complication group (P < 0.0001). The cumulative incidence of DSM was also significantly worse in patients with complications (P < 0.0001). Multivariate analysis identified the same significant increasing risk of complication for both OS (hazard ratio 1.88; 95 % confidence interval 1.26–2.80) and DSM (hazard ratio 1.90; 95 % confidence interval 1.19–3.02).

Conclusions

Postoperative complications that can cause prolonged inflammation have an obvious impact not only on the OS but also on the DSM of patients with gastric cancer even if the tumor is resected curatively.

Keywords

Gastric Cancer Overall Survival Anastomotic Leakage Laparoscopic Gastrectomy Gray Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The authors declare no conflict of interest.

References

  1. 1.
    Rivera F, Vega-Villegas ME, López-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007;33:315–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Maehara Y, Hasuda S, Koga T, et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87:353–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Adachi Y, Oshiro T, Mori M, et al. Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer. 1996;77:2445–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Roukos DH, Kappas AM. Limitations in controlling risk for recurrence after curative surgery for advanced gastric cancer are now well-explained by molecular-based mechanisms. Ann Surg Oncol. 2001;8:620–1.PubMedCrossRefGoogle Scholar
  5. 5.
    Isobe Y, Nashimoto A, Akazawa K, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011;14:301–16.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Walker KG, Bell SW, Rickard MJ, et al. Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg. 2004;240:255–9.PubMedCrossRefGoogle Scholar
  7. 7.
    McArdle CS, McMillan DC, Hole DJ. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg. 2005;92:1150–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 2009;250:798–807.PubMedCrossRefGoogle Scholar
  9. 9.
    Rizk NP, Bach PB, Schrag D, et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004;198:42–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Sierzega M, Kolodziejczyk P; Kulig J. Polish Gastric Cancer Study Group. Impact of anastomotic leakage on long-term survival after total gastrectomy for carcinoma of the stomach. Br J Surg. 2010;97:1035–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Yoo HM, Lee HH, Shim JH, et al. Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol. 2011;104:734–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th edition. New York: Wiley-Blackwell; 2010.Google Scholar
  13. 13.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  16. 16.
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.CrossRefGoogle Scholar
  17. 17.
    Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980.Google Scholar
  18. 18.
    Roder JD, Böttcher K, Siewert JR, et al. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study, 1992. Cancer. 1993;72:2089–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Kodera Y, Sasako M, Yamamoto S, et al; Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg. 2005;92:1103–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Hosono S, Arimoto Y, Ohtani H, et al. Meta-analysis of short term outcomes after laparoscopic-assisted distal gastrectomy. World J Gastroenterol. 2006;12:7676–83.PubMedGoogle Scholar
  22. 22.
    Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc. 2005;19:168–73.PubMedCrossRefGoogle Scholar
  23. 23.
    Adachi Y, Shiraishi N, Shiromizu A, et al. Laparoscopy-assisted Billroth I gastrectomy compared with conventional open gastrectomy. Arch Surg. 2000;135:806–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Kitano S, Shiraishi N, Fujii K, et al. A randomized controlled trial comparing open vs laparoscopyassisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery. 2002;131:306–11.CrossRefGoogle Scholar
  25. 25.
    Mochiki E, Nakabayashi T, Kamimura H, et al. Gastrointestinal recovery and outcome after laparoscopy-assisted versus conventional open distal gastrectomy for early gastric cancer. World J Surg. 2002;26:1145–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.PubMedCrossRefGoogle Scholar
  27. 27.
    Danielson H, Kokkola A, Kiviluoto T, et al. Clinical outcome after D1 vs D2–3 gastrectomy for treatment of gastric cancer. Scand J Surg. 2007;96:35–40.PubMedGoogle Scholar
  28. 28.
    Memon MA, Subramanya MS, Khan S, et al. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Ann Surg. 2011;253:900–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.PubMedCrossRefGoogle Scholar
  30. 30.
    Mimori K, Fukagawa T, Kosaka Y, et al. Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res. 2008;14:2609–16.PubMedCrossRefGoogle Scholar
  31. 31.
    Arigami T, Uenosono Y, Hirata M, et al. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci. 2011;102:1019–24.PubMedCrossRefGoogle Scholar
  32. 32.
    Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–44.PubMedCrossRefGoogle Scholar
  33. 33.
    McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Takeshi Kubota
    • 1
  • Naoki Hiki
    • 1
  • Takeshi Sano
    • 1
  • Shogo Nomura
    • 2
  • Souya Nunobe
    • 1
  • Koshi Kumagai
    • 1
  • Susumu Aikou
    • 1
  • Ryohei Watanabe
    • 1
  • Toshiyuki Kosuga
    • 1
  • Toshiharu Yamaguchi
    • 1
  1. 1.Department of Gastroenterological SurgeryCancer Institute Hospital, Japanese Foundation for Cancer ResearchKoto-kuJapan
  2. 2.Department of BiostatisticNational Cancer CenterKashiwaJapan

Personalised recommendations